<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05041803</url>
  </required_header>
  <id_info>
    <org_study_id>CP543.5002</org_study_id>
    <secondary_id>2021-002365-18</secondary_id>
    <nct_id>NCT05041803</nct_id>
  </id_info>
  <brief_title>European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata</brief_title>
  <official_title>A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Concert Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Concert Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess&#xD;
      long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate&#xD;
      to severe alopecia areata. Patients from European sites who previously completed a qualifying&#xD;
      CTP-543 clinical trial may participate in this study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of CTP-543 on treating hair loss as measured by the Severity of Alopecia Tool (SALT)</measure>
    <time_frame>52 weeks</time_frame>
    <description>SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Alopecia Areata</condition>
  <arm_group>
    <arm_group_label>CTP-543</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who previously completed a qualifying CTP-543 clinical trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTP-543</intervention_name>
    <description>Twice daily dosing</description>
    <arm_group_label>CTP-543</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have completed 24 weeks of treatment in a previous qualifying CTP-543 clinical trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical&#xD;
             treatment to the scalp, significant trauma to the scalp, or untreated actinic&#xD;
             keratosis&#xD;
&#xD;
          -  Females who are nursing, pregnant, or planning to become pregnant while in the study,&#xD;
             and for 30 days after last dose of study medication&#xD;
&#xD;
          -  Donation of blood at any point throughout the study and for 30 days after last dose of&#xD;
             study medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Colleen E. Hamilton, MS</last_name>
    <phone>781-674-5228</phone>
    <email>chamilton@concertpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital La Timone-Dermatologie</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis, Centre de Santé Sabouraud</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ot.Co Clinic Klinika Osipowicz &amp; Turkowski Sp. Z O.O.</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>00-716</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vita Longa Sp.Zo.O</name>
      <address>
        <city>Katowice</city>
        <zip>40-748</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>SGD S.C.</name>
      <address>
        <city>Kraków</city>
        <zip>31-147</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>My Clinic</name>
      <address>
        <city>Warsaw</city>
        <zip>00-144</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royalderm Agnieszka Nawrocka</name>
      <address>
        <city>Warsaw</city>
        <zip>02-962</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 3, 2021</study_first_submitted>
  <study_first_submitted_qc>September 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

